Given the lack of inpatient trials specifically focusing on SGLT2is for hyperglycemia management and given ample data supporting the safe use of basal-bolus insulin or DPP4is, current guidelines advise against using SGLT2is for managing hyperglycemia in hospital settings [7, 9, 11]. Here, INS is linked to Hyperglycemia.